Ronald C. Rubenstein

Author

Also Known As

Accurso, Frank J., Carlos Milla, Dorkin, Henry L, Kuhn, R C Rubenstein, R Leonard, R RUBENSTEIN, R Rubenstein, R. C. Rubenstein, R. Rubenstein

139

Publications

7.9K

Citations

H-Index

105

Concepts

All Affiliations

University of Pennsylvania Children's Hospital of Philadelphia University of Pittsburgh Hospital of the University of Pennsylvania Washington University in St. Louis

About

Ronald C. Rubenstein is an author at University of Pennsylvania specializing in medicine, cellular physiology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	33	3.9K
2	Health Sciences	6	6	194
3	Natural Sciences	5	5	339
4	Education	1	1	15
5	Engineering	1	1	13

Ronald C. Rubenstein

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial Harry Heijerman, Edward F. McKone, D.G. Downey, The Lancet Mendelian DisorderGeneticsIvacaftor Combination RegimenF508del MutationMedicine	2019	1.3K
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation Frank J. Accurso, Steven M. Rowe, John P. Clancy, New England Journal of Medicine	2010	798
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation John P. Clancy, Steven M. Rowe, Frank J. Accurso, Thorax	2011	493
In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. Ronald C. Rubenstein, Marie E. Egan, Pamela L. Zeitlin Journal of Clinical Investigation Molecular RegulationCellular PhysiologyMolecular PharmacologyTranscriptional RegulationMembrane Transport	1997	385
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial Félix Ratjen, Christopher Hug, Gautham Marigowda, The Lancet Respiratory Medicine Pulmonary FibrosisMedicinePlacebo-controlled Phase 3	2017	291
Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR Ronald C. Rubenstein, Pamela L. Zeitlin American Journal of Physiology-Cell Physiology	2000	265
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study Margaret Rosenfeld, Claire Wainwright, Mark Higgins, The Lancet Respiratory Medicine MedicineCftr Gating MutationPediatricsIvacaftor Treatment	2018	262
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial Richard B. Moss, Patrick A. Flume, J.S. Elborn, The Lancet Respiratory Medicine Antifibrotic TherapyPathologyPulmonary FibrosisArg117his-cftr MutationMedicine	2015	223
Phase II studies of nebulised Arikace in CF patients with<i>Pseudomonas aeruginosa</i>infection John P. Clancy, Lieven Dupont, Michael W. Konstan, Thorax	2013	218
Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate Pamela L. Zeitlin, Marie Diener‐West, Ronald C. Rubenstein, Molecular Therapy	2002	193

Page 1